Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2003

View Archived Issues

Thyroid hormone receptor beta agonists: novel class of agents for lipoprotein disorders and obesity

First antithrombotic agent that acts by inhibiting Bruton's tyrosine kinase (BTK)

Good pharmacokinetic and safety profile reported for the new antidiabetic drug tesaglitazar

Effective termination of AF with intravenous RSD-1235

Evotec and DeveloGen enter obesity and diabetes partnership

Preclinical results reported for AZ-CINN-310 in breast cancer

Kinase inhibitors under study at Bayer

New antipsychotic dopamine D2 and/or D3 receptor ligands identified at GSK

Guanidine-based 5-HT6 receptor ligands in early development at Wyeth

Novel GSK-3 inhibitors, their preparation and use claimed by GSK scientists

Schering researchers present new inhibitors of IL-12 and IFNgamma production

Novel chemokine CCR3 receptor antagonists in GSK pipeline

BMS and QDose collaborate on inhaled insulin product development

Antisoma licenses telomerase inhibitor program

Depakote ER approved for pediatric epilepsy

European agreement covers Orthovisc distribution

Vitaxin enters phase II trials in melanoma and rheumatoid arthritis

Dosing begins in phase Ib West Nile virus study of AVI-4020

Philip Morris grant supports TNT-based lung cancer research

Bioenvision obtains clofarabine option in Japan and South East Asia

First approval for Cubicin, Cubist's once-daily antibiotic for skin and skin structure infections

Advisory committee does not recommend approval of Metvix for basal cell carcinoma

Market launch announced for Aloxi

Dihydroxypyridone monobactam PTX-2416 for resistant Gram-negative infections

Potent, orally active and rapid-acting PDE5 inhibitor discovered at Schering-Plough

Roche synthesizes peptide with potent alpha4 integrin-antagonist activity

New series of fatty acid oxidation inhibitors designed at CV Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...